Evidence map›Paper›PMID 40294026›Full record

ArticlePLoS neglected tropical diseases2025

Proceedings of the second annual dengue endgame summit: A call to action.

Céline S C Hardy, Lauren E Bahr, Alan L Rothman, Kathryn B Anderson, Giovanna Barba-Spaeth, Daniela Weiskopf, Eng Eong Ooi, Ernesto T A Marques, Mattia Bonsignori, Alan D T Barrett and 17 more

Abstract readConference Proceedings
In one paragraph

Article in PLoS neglected tropical diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

27 authors.

Céline S C HardyDepartment of Microbiology and Immunology, Upstate Medical University, Syracuse, New York, United States of America.
Lauren E BahrDepartment of Microbiology and Immunology, Upstate Medical University, Syracuse, New York, United States of America.
Alan L RothmanDepartment of Cell and Molecular Biology, Institute for Immunology and Informatics, University of Rhode Island, Kingston, Rhode Island, United States of America.
Kathryn B AndersonDepartment of Microbiology and Immunology, Upstate Medical University, Syracuse, New York, United States of America.
Giovanna Barba-SpaethUnité de Virologie Structurale, Institut Pasteur, Université Paris Cité, CNRS UMR 3569, Paris, France.
Daniela WeiskopfCenter for Vaccine Innovation, La Jolla Institute for Immunology, La Jolla, California, United States of America.
Eng Eong OoiProgram in Emerging Infectious Diseases, Duke-NUS Medical School, SingaporeSingapore.
Ernesto T A MarquesDepartment of Infectious Diseases and Microbiology, School of Public Health, University of Pittsburgh, Pittsburgh, Pennsylvania, United States of America.
Mattia BonsignoriTranslational Immunobiology Unit, Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, United States of America.
Alan D T BarrettSealy Institute for Vaccine Sciences and Department of Pathology, University of Texas Medical Branch, Galveston, Texas, United States of America.
Beth D KirkpatrickDepartment of Microbiology and Molecular Genetics, Larner College of Medicine, The University of Vermont, Burlington, Vermont, United States of America.
Priscila M S CastanhaDepartment of Infectious Diseases and Microbiology, School of Public Health, University of Pittsburgh, Pittsburgh, Pennsylvania, United States of America.
Marco Hamins-PuertolasDepartment of Medicine, University of California, San Francisco, California, United States of America.
Rebecca C ChristoffersonDepartment of Pathobiological Sciences, Louisiana School of Veterinary Medicine, Baton Rouge, Louisiana, United States of America.
George DimopoulosHarry Feinstone Department of Molecular Microbiology and Immunology, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland, United States of America.
Fabiano OliveiraLaboratory of Malaria and Vector Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, United States of America.
Lillian W ChiangEvrys Bio, Inc., Pennsylvania Biotechnology Center, Doylestown, Pennsylvania.
Albert I KoDepartment of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, Connecticut, United States of America.
Bhagwat GunaleSerum Institute of India Pvt. Ltd., Hadapsar, Pune, Maharashtra, India.
Prasad KulkarniSerum Institute of India Pvt. Ltd., Hadapsar, Pune, Maharashtra, India.
T Alex PerkinsDepartment of Biological Sciences, University of Notre Dame, Notre Dame, Indiana, United States of America.
Ilaria DorigattiMRC Centre for Global Infectious Disease Analysis and the Abdul Latif Jameel Institute for Disease and Emergency Analytics, School of Public Health, Imperial College London, London, United Kingdom.
Telisa StewartDepartment of Public Health and Preventive Medicine, Upstate Medical University, Syracuse, New York, United States of America.
Jana ShawDepartment of Pediatrics, State University of New York Upstate Medical University, Syracuse, New York, United States of America.
Michael A JohanssonBouvé College of Health Sciences and Network Science Institute, Northeastern University, Boston, Massachusetts, United States of America.
Stephen J ThomasDepartment of Microbiology and Immunology, Upstate Medical University, Syracuse, New York, United States of America.
Adam T WaickmanDepartment of Microbiology and Immunology, Upstate Medical University, Syracuse, New York, United States of America.ORCID 0000-0002-4536-6714

Funding

State of New York (ATW)
6 · The paper itself

Abstract

On August 7-9, 2024, the second annual dengue "endgame" summit was held in Syracuse, NY, hosted by the Global Health Institute at SUNY Upstate Medical University. The meeting brought together attendees from around the world, with talks spanning healthcare, government control programs, basic research, and medical countermeasure development efforts. The summit goal was to work toward a better understanding of what dengue control could look like and the steps required to reach such a goal. The objectives of the meeting were to discuss the current global state of dengue, what dengue "control" might look like, and to discuss actionable pathways for achieving dengue control. Topics covered throughout the meeting included DENV immunity and pathogenesis, challenges in countermeasure development, innovative vector control strategies, dengue diagnostics, addressing challenges in science communication, and vaccine hesitancy. Several fundamental knowledge gaps were repeatedly highlighted by the summit attendees and were cited as critical barriers to the development, deployment, and evaluation of effective dengue countermeasures. These gaps include (1) the lack of a broadly applicable immunologic biomarker/correlate of DENV immunity and (2) the lack of universally accepted/applicable metrics for quantifying dengue severity in the setting of countermeasure evaluations. In addition, the lack of clear and consistent international leadership in the global dengue control effort was cited as a barrier to widespread and synergistic research and countermeasure development/deployment activities. Despite these persistent roadblocks, summit attendees expressed optimism that holistic and multi-tiered approaches-incorporating optimal use of existing and nascent countermeasure technologies deployed in collaboration with local communities-could be effective in progressing toward dengue control.

Indexed as

DengueAnimalsDengue VaccinesDengue VirusGlobal HealthHumansDengue Vaccines

Identifiers

PMID40294026
PMCPMC12036847

What OpenQuestion holds

Textmetadata
LicenceCC0
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.